In Week of Mar 28, 2026, Alkem Laboratories Ltd (Pharma - Formulators) is outperforming Nifty 500 with +8.2% relative strength. Fundamentals: Weak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Mar 28, 2026
What: International business growing at 26.6% YoY (vs domestic 5.5%), now representing 32.5% of total revenue
Impact: +₹3200 Cr revenue
“International sales were at 12,157 million with a YoY growth of 26.6%”
What: Chronic business growing 2x market in pain management, 1.8x in derma, >2x in antidiabetic (excluding GLP1)
Impact: +₹1800 Cr revenue
“We are growing 2x of the market pain at 1.4x. Antidiabetic is 1.2x but if I adjust for the GLP1 it is more than 2x of the market respiratory 1.2x and derma 1.8x.”
What: Domestic business returning to strong double-digit growth after Q3 FY25 channel optimization
Impact: +₹2500 Cr revenue
“So if we adjust the base effect, there has been a still strong double digit growth of domestic business that continues even in Q3 of FY26.”
Earnings deceleration risks from management commentary
Trigger: Domestic business growth <10%
Impact: -160 bps margin impact
Management view: We delivered a stable performance in a dynamic operating environment supported by strong fundamentals in our domestic business
Monitor: Domestic revenue growth rate
Trigger: Recurring exceptional items
Management view: Exceptional item for the quarter includes the impact of ₹ 528 million on a preliminary basis
Monitor: Exceptional items in next quarter
Key quotes from recent conference calls
“In Q3 we delivered a stable performance in a dynamic operating environment supported by strong fundamentals in our domestic business and consistent execution across our international businesses. — Management”
“International sales were at 12,157 million with a YoY growth of 26.6% — Management”
“Our chronic business is seeing very strong growth trajectory both YTD as well as quarter for this year. We are growing 2x of the market pain at 1.4x. Antidiabetic is 1.2x but if I adjust for the GLP1 it is more than 2x of the market respiratory 1.2x and derma 1.8x. — Management”
“During Q3 of last year we undertook measured adjustment to our distribution setup in certain areas which was aimed at strengthening the channel effectiveness and improving the service levels and supporting overall long term growth. So we had realized certain sales in Q3 FY25 which led to a high base for that quarter. So if we adjust the base effect, there has been a still strong double digit growth of domestic business that continues even in Q3 of FY26. — Management”
Forward-looking targets from management for Full year FY26
Key Milestones
• Deliver full year guidance
• Maintain international growth momentum
• Domestic business recovery
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +11% | +7% | Stable |
| PAT (Net Profit) | +2% | +10% | Stable |
| OPM | 22.0% | -100 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 28, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Alkem Laboratories Ltd's latest quarterly results (Dec 2025) show
Alkem Laboratories Ltd's profit is growing with an stable trend.
Alkem Laboratories Ltd's revenue growth trend is stable.
Alkem Laboratories Ltd's operating margin is stable.
Alkem Laboratories Ltd's long-term compounding rates
Alkem Laboratories Ltd's earnings growth is stable with weakening on a sequential basis.
Alkem Laboratories Ltd's trailing twelve month (TTM) performance
Alkem Laboratories Ltd appears fairly valued based on our fair value analysis.
Alkem Laboratories Ltd's current PE ratio is 26.6x.
Alkem Laboratories Ltd's current PE is 26.6x.
Alkem Laboratories Ltd's price-to-book ratio is 4.8x.
Alkem Laboratories Ltd is rated Weak with a fundamental score of 33.61/100. This score is calculated from objective financial metrics
Alkem Laboratories Ltd has a debt-to-equity ratio of N/A.
Alkem Laboratories Ltd's return ratios over recent years
Alkem Laboratories Ltd's operating cash flow is positive (FY2025).
Alkem Laboratories Ltd's current dividend yield is 0.84%.
Alkem Laboratories Ltd's shareholding pattern (Dec 2025)
Alkem Laboratories Ltd's promoter holding has remained stable recently.
Alkem Laboratories Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Alkem Laboratories Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Alkem Laboratories Ltd has 3 key growth catalysts identified from recent earnings analysis
Alkem Laboratories Ltd has 2 key risks worth monitoring
In Q3 FY26, Alkem Laboratories Ltd's management highlighted
Alkem Laboratories Ltd's management has provided the following forward guidance for Full year FY26
Based on quantitative research signals, here is why Alkem Laboratories Ltd may be worth studying
Alkem Laboratories Ltd investment thesis summary:
Alkem Laboratories Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
